CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (13,442,221)	$ (7,134,957)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	398,989	96,922
Amortization of warrant asset	165,026	0
Write down of fixed assets to net realizable value	4,874,917	1,721,663
Loss from equity method investment	28,619	437,375
Expensing (recovery) of related party debt	(444,962)	1,470,522
Stock based compensation and shares issued with debt issuances	448,956	248,103
Gain on conversion of notes payable	0	30,654
Gain on disposal of assets	0	10,690
Changes in operating assets and liabilities, net of acquisitions:
Trade receivables, net	263,910	(87,023)
Trade receivables, related parties	5,100	132,197
Prepaid expenses	516,654	225,715
Prepaid expenses, related parties	35,609	0
Inventories	(1,193,534)	(446,196)
Accounts payable	1,831,839	315,149
Accounts payable - related parties	(7,910)	(119,574)
Accrued liabilities	798,224	17,485
ROU assets and liabilities	(57,706)	0
ROU assets and liabilities: related party	(17,182)	1,028
Deferred revenues	(49,135)	(1,290,229)
Net cash used in operating activities	(5,844,807)	(4,370,476)
Cash flows from investing activities:
Purchases of property, plant and equipment	(179,390)	(103,868)
Loans to related parties	(2,912,034)	0
Purchase of intangibles	(230,911)
Cash paid for acquisition of Green Star Labs	(289,730)	0
Proceeds from disposal of equipment	0	40,000
Net cash used in investing activities	(3,612,065)	(63,868)
Cash flows from financing activities:
Equipment loan proceeds / (repayments)	0	(300,900)
Payment on short term loans	(6,597)
Proceeds from convertible notes payable	2,031,582
Proceeds from short-term loans and lines of credit	100,000	0
Repayments to related parties	(150,000)	(1,480,122)
Proceeds from short-term promissory note, related parties	432,982	50,000
Investment in Joint Venture	0	50,000
Proceed from sale of common stock	7,244,999	6,416,000
Offering costs paid in connection with sale of common stock	(634,600)	(685,772)
Net cash provided by financing activities	9,018,366	4,049,206
Decrease in cash and cash equivalents	(438,506)	(385,138)
Cash and cash equivalents at beginning of period	548,331	933,469
Cash and cash equivalents at end of period	109,825	548,331
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash Paid for Interest	83,763	0
Cash Paid for Taxes	5,654	3,474
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Common stock issued in satisfaction of notes payable and accrued interest	146,940	56,592
Warrants issued with convertible notes	0	437,375
Marketing services and financing costs paid with shares or warrants	463,009	0
Accounts payable paid with shares	0	91,864
Purchase of equipment with short-term financing	137,640
Capital contribution by partner for equity in joint venture	0	50,000
Notes payable incurred in connection with acquisition of Green Star Labs	3,200,000	0
Increase in related party notes payable in connection with acquisition of Green Star Labs	687,647
Payment for equipment and intangible assets with shares	0	4,000,000
Net liabilities incurred in connection with Green Star Labs	838,093	0
Equipment loan repaid with shares	$ 0	$ 1,213,335